In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biovail buys Valeant in $3.3bn reverse merger

Executive Summary

Biovail Corp. has agreed to acquire Valeant Pharmaceuticals International in a reverse merger valued at $3.3bn that will build a specialty pharma company with projected revenues of $1.75bn. Valeant shareholders will receive $43.23--consisting of $16.77 in cash and 1.7809 in Biovail shares for each Valeant share they own. Biovail will have a 50.5% stake in the combined company, and Valeant owns the remainder.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Acquisition
    • Reverse Acquisition
    • Payment Includes Stock
    • Full Acquisition
    • Payment Includes Cash

Related Companies